CDK2-IN-18, identified by its CAS number 364735-73-9, is a chemical compound that serves as an inhibitor of cyclin-dependent kinase 2 (CDK2), an important enzyme involved in cell cycle regulation. This compound is characterized by its ability to selectively bind to the ATP-binding site of CDK2, thereby preventing its interaction with cyclins and inhibiting its kinase activity. The inhibition of CDK2 is significant in cancer research, as dysregulation of this enzyme is often associated with uncontrolled cell proliferation. CDK2-IN-18 is typically studied in the context of its potential therapeutic applications in oncology, particularly for tumors that exhibit overactive CDK2 signaling. The compound's structure includes specific functional groups that contribute to its binding affinity and selectivity, making it a valuable tool in the development of targeted cancer therapies. Additionally, its pharmacokinetic properties, such as solubility and stability, are crucial for its efficacy in biological systems. Overall, CDK2-IN-18 represents a promising candidate for further investigation in the field of cancer treatment.

CDK2-IN-18

364735-73-9: CDK2-IN-18, identified by its CAS number 364735-73-9, is a chemical compound that serves as an inhibitor of cyclin-dependent kinase 2 (CDK2), an important enzyme involved in cell cycle regulation. This compound is characterized by its ability to selectively bind to the ATP-binding site of CDK2, thereby preventing its interaction with cyclins and inhibiting its kinase activity. The inhibition of CDK2 is significant in cancer research, as dysregulation of this enzyme is often associated with uncontrolled cell proliferation. CDK2-IN-18 is typically studied in the context of its potential therapeutic applications in oncology, particularly for tumors that exhibit overactive CDK2 signaling. The compound's structure includes specific functional groups that contribute to its binding affinity and selectivity, making it a valuable tool in the development of targeted cancer therapies. Additionally, its pharmacokinetic properties, such as solubility and stability, are crucial for its efficacy in biological systems. Overall, CDK2-IN-18 represents a promising candidate for further investigation in the field of cancer treatment.

<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>

CAS 364735-73-9

CDK2-IN-18

CDK2-IN-18

Ref: TM-T86027